Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Gamida Cell Ltd. (Nasdaq: GMDA) will present corporate highlights at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 2:00 p.m. ET. The presentation will be accessible via webcast on the company's website for at least 14 days post-event. Gamida Cell is focused on innovative cell therapies targeting blood cancers and serious blood diseases, with a notable investigational product, omidubicel, aimed at improving bone marrow transplant outcomes. The company leverages a proprietary expansion platform to develop potentially curative therapies.

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will present its corporate highlights at the upcoming Oppenheimer 32^nd Annual Healthcare Conference on March 16, 2022 at 2:00 p.m. ET.

The webcast will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

About Gamida Cell

Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapies with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates (including GDA-201), anticipated regulatory filings (including the timing of submission of the BLA for omidubicel to the FDA), commercialization planning efforts, and the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 9, 2021, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005680/en/

For investors:

Courtney Turiano

Stern Investor Relations, Inc.

Courtney.Turiano@sternir.com

1-212-362-1200

For media:

Rhiannon Jeselonis

Ten Bridge Communications

rhiannon@tenbridgecommunications.com

1-978-417-1946

Source: Gamida Cell Ltd.

FAQ

When will Gamida Cell be presenting at the Oppenheimer Healthcare Conference?

Gamida Cell will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 2:00 p.m. ET.

How can I access the Gamida Cell presentation?

The presentation will be available as a webcast on the Investors & Media section of Gamida Cell's website.

What is omidubicel, and what is its significance?

Omidubicel is an investigational product by Gamida Cell, designed as a potentially life-saving alternative for patients requiring a bone marrow transplant.

What type of therapies does Gamida Cell focus on?

Gamida Cell focuses on advanced cell therapies for blood cancers and serious blood diseases, targeting both solid tumors and hematological malignancies.

Where can I find more information about Gamida Cell?

For more information, visit Gamida Cell's website at www.gamida-cell.com.